Sabby Management’s Biocept, Inc. BIOC Stock Holding History

Sabby Management’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-39	Closed	-$486K	–	213
2021 Q2	$486K	Buy	39 +4	+11%	+$541	0.07%	113
2021 Q1	$528K	Buy	35 +19	+119%	+$3.45K	0.1%	106
2020 Q4	$211K	Buy	+16	New	+$2.28K	0.04%	84

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sabby Management's BIOC Position: Q2 2023 in Review

Sabby Management sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 987 shares — an estimated $10.1K sold.

Sabby Management first reported a position in BIOC in Q4 2016 and held it in 15 quarters. The position peaked at $668K in Q4 2017. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

Sabby Management reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
Sabby Management sold 987 Biocept, Inc. shares in Q2 2023, an estimated $10.1K.
Sabby Management first reported a position in Biocept, Inc. in Q4 2016 and held it in 15 quarters.
Sabby Management's Biocept, Inc. position peaked at $668K in Q4 2017.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.